Expert Video Report on standard approaches and new treatment options for DLBCL

ASH 2018, San Diego

Speaker: Umberto Vitolo

Reporting from ASH 2018, Umberto Vitolo first discusses the results from the FLYER trial that explored de-escalation of standard treatment in young, low risk DLBCL patients. Both in terms of demonstrated efficacy and reduced toxicity, these results are practice changing for selected patients.
Dr Vitolo also comments on the final results from the JULIET study which confirms the findings from preliminary analysis. He also comments on results from everyday clinical practice in the US which are very similar with what has been observed in clinical trials setting. In some selected patients who relapse after autologous stem cell transplantation, CAR-T cell therapy may be considered in clinical practice.

ASH 2018 abstracts: